TITLE

Interferon-Ribavirin in Association with Stavudine Has No Impact on Plasma Human Immunodeficiency Virus (HIV) Type 1 Level in Patients Coinfected with HIV and Hepatitis C Virus: A CORIST-ANRS HC1 Trial

AUTHOR(S)
Salmon-Céron, Dominique; Lassalle, Régis; Pruvost, Alain; Benech, Henri; Bouvier-Alias, Magali; Payan, Christopher; Goujard, Cécile; Bonnet, Eric; Zoulim, Fabien; Morlat, Philippe; Sogni, Philippe; Pérusat, Sophie; Tréluyer, Jean-Marc; Chêne, Geneviève
PUB. DATE
May 2003
SOURCE
Clinical Infectious Diseases;5/15/2003, Vol. 36 Issue 10, p1295
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A randomized, open-label trial was performed to study virological and intracellular interactions between stavudine and ribavirin in 30 patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Patients were randomized to receive either interferon and ribavirin or no treatment for HCV infection for 3 months. Intracellular peripheral blood mononuclear cells' stavudine-triphosphate (TP) concentrations were assessed. Plasma HIV RNA levels did not change significantly between baseline and month 3. There was a nonstatistically significant trend for a lower median residual concentration of intracellular stavudine-TP in the treated group, compared with the control group. The same trend was also observed for peak concentrations. Coprescription of ribavirin and stavudine has no short-term impact on plasma HIV RNA level in HIV-HCV-coinfected patients treated with stavudine as a part of their antiretroviral treatment; this coprescription can be safely used, although an in vivo interaction between ribavirin and stavudine is possible.
ACCESSION #
9768949

 

Related Articles

  • Peginterferon Plus Ribavirin for Chronic Hepatitis C in Patients With Human Immunodeficiency Virus. Gluud, Lise Lotte; Marchesini, Emanuela; Iorio, Alfonso // American Journal of Gastroenterology;Sep2009, Vol. 104 Issue 9, p2335 

    OBJECTIVES:The aim of this study was to assess the effects of peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus (HIV).METHODS:Trials were identified through manual and electronic searches. Randomized trials comparing peginterferon plus ribavirin...

  • Treatment of acute hepatitis C in HIV infection. Vogel, Martin; Rockstroh, Jürgen K. // Journal of Antimicrobial Chemotherapy (JAC);Jan2010, Vol. 65 Issue 1, p4 

    Within Europe and recently in the USA and Australia an ongoing epidemic of acute hepatitis C virus (HCV) infections among HIV-positive individuals, mainly men who have sex with men, has been observed. Other concomitant sexually transmitted diseases and sexual practices with a high risk of...

  • Modeling the Probability of Sustained Virological Response to Therapy with Pegylated Interferon plus Ribavirin in Patients Coinfected with Hepatitis C Virus and HIV. Medrano, Jose; Neukam, Karin; Rallón, Norma; Rivero, Antonio; Resino, Salvador; Naggie, Susanna; Caruz, Antonio; Calvino, Aida; Macías, Juan; Benito, Jose Miguel; Sánchez-Piedra, Carlos; Vispo, Eugenia; Barreiro, Pablo; McHutchison, John; Pineda, Juan Antonio; Soriano, Vincent // Clinical Infectious Diseases;11/15/2010, Vol. 51 Issue 10, p1209 

    Background. A single-nucleotide polymorphism (SNP) near the IL28B gene (rs12979860) strongly predicts sustained virological response to pegylated interferon plus ribavirin (pegIFN-RBV) treatment for chronic hepatitis C virus (HCV) infection. Given that therapy is poorly tolerated and rates of...

  • Review: Interferon-α plus ribavirin improves the virologic response in chronic hepatitis C. Reichen, Juerg // ACP Journal Club;Jul/Aug2002, Vol. 137 Issue 1, p17 

    Provides information on a study that examined whether interferon-α plus ribavirin more effective than interferon-α alone for improving hepatitis C virologic response and liver-related morbidity and mortality in patients with chronic hepatitis C. Data sources; Study selection; Main...

  • HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C. Romero-Gómez, Manuel; González-Escribano, María Francisca; Torres, Belén; Barroso, Natalia; Montes-Cano, Marco Antonio; Sánchez-Muñoz, Diego; Núñez-Roldan, Antonio; Aguilar-Reina, José // American Journal of Gastroenterology;Jul2003, Vol. 98 Issue 7, p1621 

    : ObjectiveThe aim of this study was to assess the influence of host genetic factors on response to combination therapy for chronic hepatitis C infection.: MethodsPatients with biopsy-proved chronic hepatitis C infection were treated with interferon alone (n = 143) or combined therapy of...

  • Immunological markers predicting outcome in patients with hepatitis C treated with interferon-α and ribavirin. Lee, Silvia; Macquillan, Gerry C; Keane, Niamh M; Flexman, James; Jeffrey, Gary P; French, Martyn Ah; Brochier, Jean; Price, Patricia // Immunology & Cell Biology;Aug2002, Vol. 80 Issue 4, p391 

    Summary Type 1 (T1) cytokine responses are required for the clearance of hepatitis C virus by cytotoxic T lymphocytes, but can promote liver damage. Interferon-α (IFNα) can be expected to promote T1 cytokine responses, so treatment outcome may depend on the T1/T2 cytokine environment and...

  • Interferon-α-2b Plus Ribavirin: A Review of its Use in the Management of Chronic Hepatitis C. Scott, L.J.; Perry, C.M. // Drugs;2002, Vol. 62 Issue 3, p507 

    Relatively few patients (≤20%) with chronic hepatitis C achieve a sustained virological response after interferon-α monotherapy. Hence, alternative treatment strategies such as the addition of the broad spectrum antiviral agent ribavirin to interferon-α-2b have been investigated....

  • Spontaneous Hepatic Decompensation in Patients Coinfected with HIV and Hepatitis C Virus during Interferon-Ribavirin Combination Treatment. Bani-Sadr, Firouzé; Carrat, Fabrice; Rosenthal, Eric; Piroth, Lionel; Morand, Patrice; Lunel-Fabiani, Françoise; Bonarek, Mojgan; de Verdiere, Nathalie Cohn; Pialoux, Gilles; Cacoub, Patrice; Pol, Stanislas; Perronne, Christian // Clinical Infectious Diseases;12/15/2005, Vol. 41 Issue 12, p1806 

    Spontaneous hepatic decompensation was observed in 7 of 383 patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) who were receiving treatment with interferon and ribavirin. Multivariate analysis identified the following risk factors: didanosine use (odds ratio...

  • Chronic Hepatitis C in HIV-Infected Patients: Those Who More Need Therapy are Those Who Respond Less. Soriano, Vincent; Nu�ez, Marina; Garcia-Samaniego, Javier; Labarga, Pablo; Simarro, Nuria; Martin-Carbonero, Luz; Ramos, Belen; Barreiro, Pablo // Infectious Disorders - Drug Targets;Mar2006, Vol. 6 Issue 1, p57 

    One third of HIV-infected individuals worldwide suffer from chronic hepatitis C virus (HCV) infection. Two main reasons justify considering HCV therapy as a priority in HIV-coinfected patients. First, these patients have more rapid liver disease progression, and second, they have a higher risk...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics